Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Lam Discusses Agents for ROS1-Mutated NSCLC

November 3rd 2017

Vincent Lam, MD, assistant professor, The University of Texas MD Anderson Cancer, discusses agents to target ROS1-mutated non-small cell lung cancer (NSCLC).

Osimertinib Continues to Show Impressive Activity in EGFR+ NSCLC

November 2nd 2017

Mary Jo Fidler, MD, discusses targeting the EGFR-gene activating mutations, first- and second-generation inhibitors, and the potential of osimertinib.

Dr. Garassino on Immunotherapy in EGFR-Mutated Lung Cancer

November 1st 2017

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses immunotherapy for patients with EGFR-mutated lung cancer.

Dr. Oxnard on the Role of Osimertinib in the TATTON Trial for Lung Cancer

November 1st 2017

Geoffrey R. Oxnard, MD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the role of osimertinib (Tagrisso) in the TATTON trial for patients with lung cancer.

Dr. Camidge Discusses Unmet Needs in ALK+ Lung Cancer

November 1st 2017

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses unmet needs for patients with ALK-positive lung cancer.

Dr. Garissino on Combinations With Immune Checkpoint Inhibitors in NSCLC

October 31st 2017

Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses combinations with immune checkpoint inhibitors in non-small cell lung cancer.

CDK4/6 Inhibitors Explored in KRAS-Mutant Cancers

October 31st 2017

A new generation of more selective inhibitors of CDK4 and CDK6 has entered the clinic in combination therapies for patients with breast cancer. These agents also are being investigated in patients with KRAS-mutant malignancies.

Dr. Doebele Discusses Brain Metastases in ROS1+ NSCLC

October 31st 2017

Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses brain metastases in ROS1-positive non-small cell lung cancer.

Merck Withdraws EU Application for Frontline Pembrolizumab Combo in NSCLC

October 30th 2017

Merck has announced that it has withdrawn its European application for pembrolizumab in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer.

Progression Issues Surface With NSCLC Immunotherapy

October 27th 2017

Paul A. Bunn Jr, MD, discusses strategies for analyzing and responding to signs of progression for patients receiving immunotherapy for non-small cell lung cancer.

Dr. Gandhi Discusses the Role of Alectinib in ALK+ Lung Cancer

October 26th 2017

Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses the role of alectinib (Alecensa) in patients with ALK-positive non-small cell lung cancer (NSCLC).

Expert Calls for Clinical Trial Referrals in Molecularly Targetable NSCLC

October 26th 2017

Victoria M. Villaflor, MD, discusses driver mutations in NSCLC and remaining challenges in treating patients with targetable disease.

Dr. Camidge on the Unmet Needs for Lung Cancer

October 25th 2017

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses unmet needs for patients with lung cancer.

Dr. Drilon on MET-Amplified Lung Cancer

October 25th 2017

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of MET in patients with lung cancer.

Frontline Pembrolizumab More Than Doubles OS in PD-L1+ NSCLC

October 19th 2017

Two-year results showed that frontline pembrolizumab (Keytruda) more than doubled median overall survival compared with standard chemotherapy in patients with high PD-L1 expressing non–small cell lung cancer

Ado-Trastuzumab Emtansine Shows Activity in HER2-Mutated, Amplified Lung Cancer

October 19th 2017

Ado-trastuzumab emtansine (Kadcyla) is active and well tolerated in patients with advanced HER2-mutant or amplified lung cancers as identified by next generation sequencing.

Entrectinib Impresses for ROS1-Positive NSCLC

October 18th 2017

Treatment with entrectinib induced an objective response rate of 68.8% by blinded independent central review, which included 2 complete responses (6.3%), for patients with ROS1 fusion-positive advanced non–small cell lung cancer.

Ensartinib Effective, Well-Tolerated in Patients With ALK+, TKI-Naive NSCLC

October 18th 2017

The potent small molecule TKI ensartinib has shown promise and meaningful intercranial activity in ALK-positive, TKI-naïve patients with non–small cell lung cancer.

Frontline Lorlatinib Induces 90% Response in ALK+ NSCLC

October 18th 2017

Lorlatinib induced an objective response rate of 90% in treatment-naïve patients with ALK-positive non–small cell lung cancer.

Durvalumab Delivers on QoL Post Chemo RT in PACIFIC Trial

October 18th 2017

Patient reported outcomes from the PACIFIC trial of durvalumab versus placebo after chemoradiation in locally advanced unresectable NSCLC show that durvalumab had no serious impact on quality of life.